Helicobacter pylori eradication: A randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics

American Journal of Gastroenterology

Volumn 102, Issue 5, 2007, Pages 951-956

  De Bortoli, Nicola ^a   Leonardi, Giulia ^a   Ciancia, Eugenio ^b   Merlo, Andrea ^a   Bellini, Massimo ^a   Costa, Francesco ^a   Mumolo, Maria Gloria ^a   Ricchiuti, Angelo ^a   Cristiani, Fabrizio ^a   Santi, Stefano ^b   Rossi, Mauro ^b   Marchi, Santino ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BACTERIAL ANTIGEN; CLARITHROMYCIN; DICOFARM; ESOMEPRAZOLE; LACTOFERRIN; PROBINUL CADIGROUP; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SUCRALFATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ANXIETY; ARTICLE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED HEADACHE; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; GLOSSITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INSOMNIA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS SALIVARIUS; LACTOBACILLUS SPOROGENES; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STANDARD; STREPTOCOCCUS THERMOPHILUS; TASTE; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; OMEPRAZOLE; PROBIOTICS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34247862031     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01085.x     Document Type: Article

References (40)

1. Malfertheiner P, Megraud F, O'Morain C, et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002 16 : 167 80.
2. Vergara M, Vallve M, Gisbert JP, et al. Meta-analysis: Comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003 18 : 647 54.
3. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med 1996 100 : 42S 51S.
4. Arnold RR, Brewer M, Gauthier JJ. Bactericidal activities of human lactoferrin: Sensitivity of a variety of microrganisms. Infect Immun 1980 28 : 893 8.
5. Bellamy W, Takase M, Yamauchi K, et al. Identification of the bactericidal domain of lactoferrin. Biochem Biophys Acta 1992 1121 : 130 6.
6. de Vrese M, Schrezenmeir J. Probiotics and non-intestinal infectious conditions. Br J Nutr 2002 88 (suppl 1 ss59-66.
7. Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: A prospective randomized double-blind study. J Clin Gastroenterol 2005 39 : 692 8.
8. Johnson-Henry KC, Mitchell DJ, Avitzur Y, et al. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004 49 : 1095 102.
9. Sgouras D, Maragkoudakis P, Petraki K, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004 70 : 518 26.
10. Felley C, Michetti P. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol 2003 17 : 785 91.
11. Marchi S, Costa F, Bellini M, et al. Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001 13 : 547 50.
12. Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001 13 : 1457 65.
13. McLoughlin R, Racz I, Buckley M, et al. Therapy of Helicobacter pylori. Helicobacter 2004 9 (suppl 1 42 8.
14. Altintas E, Sezgin O, Ulu O, et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004 10 : 1656 8.
15. Toracchio S, Marzio L. Primary and secondary resistance to Helicobacter pylori strain isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003 35 : 541 5.
16. Tankovic J, Lamarque D, Lascols C, et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin- clarithromycin therapy. Aliment Pharmacol Ther 2001 15 : 707 13.
17. Heep M, Kist M, Strobel S, et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000 19 : 538 41.
18. Dial EJ, Hall LR, Serna H, et al. Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 1998 43 : 2750 6.
19. Brock JH. Lactoferrin in human milk: Its role in iron absorption and protection against enteric infection in the newborn infant. Arch Dis Child 1980 55 : 417 21.
20. Schryvers AB, Bonnah R, Yu RH, et al. Bacterial lactoferrin receptors. Adv Exp Med Biol 1998 443 : 123 33.
21. Levay P, Viljoen M. Lactoferrin: A general review. Haematologica 1995 80 : 252 67.
22. Arnold RR, Cole MF, McGhee JR. A bactericidal effect for human lactoferrin. Science 1977 197 : 263 5.
23. Yamauchi K, Tomita M, Giehl TJ, et al. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993 61 : 719 28.
24. Naidu SS, Svensson U, Kishore AR, et al. Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 1993 37 : 240 5.
25. Wada T, Aiba Y, Shimizu K, et al. The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol 1999 34 : 238 43.
26. Jeremy B. Lactoferrin: A multifunctional immunoregulatory protein? Immunol Today 1995 16 : 417 9.
27. Jones EM, Smart A, Bloomberg G, et al. Lactoferricin, a new antimicrobial peptide. J Appl Bacteriol 1994 77 : 208 14.
28. Di Mario F, Aragona G, Dal Bo N, et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 2003 35 : 706 10.
29. Di Mario F, Aragona G, Dal Bo N, et al. Bovine lactoferrin for Helicobacter pylori eradication: An open, randomized, multicentre study. Aliment Pharmacol Ther 2006 23 : 1235 40.
30. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agent. A neglected modality for the treatment and prevention of selected intestinal and vaginal infection. J Am Med Assoc 1996 275 : 870 6.
31. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000 14 : 1625 9.
32. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yoghurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002 6 : 1669 75.
33. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999 60 : 203 9.
34. de Vrese M, Schrezenmeir J. Probiotics and non-intestinal infectious conditions. Br J Nutr 2002 88 (suppl 1 S59 66.
35. Nakajima S, Setoguchi Y, Yamamoto S. Effect of probiotics on the prevention of diarrhea in Helicobacter pylori therapy. Nippon Rinsho 2005 63 (suppl 11 539 42.
36. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005 21 : 1263 72.
37. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001 15 : 163 9.
38. Fukushima Y, Kawata Y, Hara H, et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998 42 : 39 44.
39. Zullo A, de Francesco V, Scaccianoce G, et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: A randomised, multicentre study. Dig Liver Dis 2005 37 : 496 500.
40. Dial EJ, Romero JJ, Headon DR, et al. Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J Pharm Pharmacol 2000 52 : 1541 6.